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P U B L I S H E D B Y E L S E V I E R I N C .LettersLow Operative Mortality
Achieved With Surgical
Septal Myectomy
Role of Dedicated Hypertrophic
Cardiomyopathy Centers in the Management
of Dynamic Subaortic ObstructionTreatment of progressive heart failure, due to left
ventricular (LV) outﬂow tract obstruction and
elevated intraventricular systolic pressures, has been
a major component of hypertrophic cardiomyopathy
(HCM) disease management for 50 years (1–3).
Throughout this time, septal myectomy has been the
primary treatment option to abolish outﬂow gradi-
ents, normalize LV pressures, and relieve severe heart
failure symptoms refractory to maximal medical
management (1,2).
The role of myectomy in the HCM treatment
armamentarium has depended not only on its effec-
tiveness for relieving heart failure symptoms, but also
its safety with acceptable operative risk. Before 1990,
experience with myectomy was relatively limited
and the mortality rate relatively high (i.e., up to 8%
in the largest series from the National Institutes of
Health) (2).
Contemporary mortality data for myectomy are
well known to experts in dedicated HCM centers but
may not have penetrated sufﬁciently into the prac-
ticing general cardiology community. Therefore, this
is an opportune time to tabulate the most recent
operative mortality data from 5 major high-volume
HCM myectomy centers in North America (Table 1).
Over the most recent 15-year period, almost
3,700 isolated myectomy operations were performed
at these institutions, with a composite operative
mortality (ﬁrst 30 days) of only 0.4% (Table 1).
Operative deaths were at ages 24 to 82 years (mean
62; 6 [35%] $70 years); 44% were men. Only 6 of the
17 deaths (35%) occurred after 2010. Notably, 2 of the
4 deaths in 1 series were in patients with prior alcohol
septal ablation; surgical myectomy performed after
ablation is associated with higher risk (2).
These data establish septal myectomy, when per-
formed in experienced HCM centers, to be one ofthe safest open-heart procedures currently practiced
(i.e., risk signiﬁcantly lower than that for coronary
artery bypass grafting [2.3%], valve replacement
[3.4%; 5.7% for the mitral valve], and mitral valve
repair [1.6%]) (3) and similar to that of atrial or ven-
tricular septal defect closure. Also, myectomy is
associated with similar (if not lower) mortality than
percutaneous alcohol ablation (4).
Of particular note, post-operative mortality in
experienced HCM myectomy centers is 15-fold less
than that recently reported by Panaich et al. (5) (i.e.,
5.9%) from U.S. “real-world” community hospital or
low-volume surgical settings. Morbidity and mortal-
ity appeared to be related largely to iatrogenic com-
plete heart block from muscular resection in the area
of the atrioventricular conduction tissue (rate 9%).
Contemporary mortality data for myectomy are a
source of reassurance to many patients with HCM,
contributing to the increasing numbers of symptom-
atic patients selecting surgery over alcohol ablation.
The striking decrease in operative risk over the past
25 years is attributable to acquired surgical experi-
ence, improved intraoperative myocardial preserva-
tion, and shorter cardiopulmonary bypass times.
As underscored by guideline expert consensus
panels (1,2), septal myectomy is preferably performed
in high-volume tertiary centers staffed by skilled
surgeons experienced with the complex LV outﬂow
tract anatomy in HCM (1,2), rather than in low-volume
institutions in which this operation is rarely per-
formed. Higher patient volume and more experience
equates to lower operative risk.
Based on data in almost 3,700 consecutive severely
symptomatic patients with obstructive HCM, myec-
tomy performed in dedicated HCM centers with
experienced surgeons and staff is one of the safest
open-heart procedures, with mortality rates as low as
0.3%. Indeed, perceptions of HCM and myectomy
have been contaminated by older obsolete published
reports skewed to a grim portrayal of outcome,
including high operative mortality (1,2). Therefore,
a contemporary understanding of the safety (and
efﬁcacy) (1,2) attributable to myectomy is crucial to
assessing the role of surgery in the management
armamentarium for this disease.
The large mortality discrepancy between com-
munity hospitals and HCM centers underscores that
TABLE 1 Operative Mortality Associated With Septal Myectomy* at North American
Hypertrophic Cardiomyopathy Centers, 2000–2014
Institution
No. of
Myectomies Age (yrs) Male (%)
Operative
Deaths†
n %
Mayo Clinic, Rochester, Minnesota 1,411 51  14 55 4‡ 0.3
Cleveland Clinic, Cleveland, Ohio 1,470§ 55  14 55 6 0.4
Tufts Medical Center, Boston,
Massachusettsk
348 52  15 56 4 1.1
Toronto General, Ontario, Canada 306 49  13 62 2 0.6
Mount Sinai–St. Luke’s and
Roosevelt, New York, New York
160 53  14 48 1 0.6
Totals 3,695 54  14 55 17 0.4
*Does not include myectomy associated with valve replacement, coronary artery bypass grafting, or resection of
a subaortic membrane. †Within 30 days of the myectomy. ‡Includes 2 patients with prior alcohol septal ablation;
with these 2 patients considered nonpure myectomies, the Mayo mortality rate would be only 0.15%. §Includes
19% of patients with mitral valve repair. kNewest myectomy center with operations performed over only 11 years
with ﬁrst procedure in 2004, whereas data for the other centers encompass 15 years.
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1308surgical myectomy should be considered a special-
ized operation best performed in high-volume HCM
institutions. Promotion of dedicated HCM centers (1)
is a strategy that will undoubtedly increase the
number of surgeons with myectomy experience and
assure patients future accessibility to this important
operation and its beneﬁts.*Barry J. Maron, MD
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Gradient Predicts
Outcome in Patients With
Heart Failure and Preserved
Ejection FractionApproximately 50% of patients presenting with clin-
ical signs of heart failure are diagnosed with heart
failure with preserved ejection fraction (HFpEF) (1).
Pulmonary hypertension (PH) is a common feature of
HFpEF and predicts poor outcome. According to the
diastolic pressure gradient (DPG), deﬁned as diastolic
pulmonary arterial pressure (PAP) minus pulmonary
artery wedge pressure, PH-HFpEF can be classiﬁed
into passive PH (DPG <7 mm Hg) and mixed PH
(DPG $7 mm Hg). The main mechanism underlying
passive PH is simple backward transmission of
elevated left-sided ﬁlling pressures with a passive
increase in pulmonary vascular pressures (2). In
patients with mixed PH, a superimposed active
component caused by pulmonary arterial vasocon-
striction and/or vascular remodeling of the small
pulmonary arteries can lead to a further increase in
PAP (2). In the present single-center study, the prev-
alence and prognostic signiﬁcance of DPG elevation
were investigated in a well-deﬁned pure HFpEF
population.
Between 2010 and 2014, a total of 174 patients with
HFpEF (mean age 71  8 years; 64.9% female), diag-
nosed according to current guidelines (3), were pro-
spectively enrolled in a dedicated registry. PH-HFpEF
was conﬁrmed if pulmonary artery wedge pressure
was >12 mm Hg and mean PAP was $25 mm Hg as
measured by right heart catheterization. The primary
study endpoint was hospitalization for heart failure
or cardiac death.
The study cohort consisted of 26 HFpEF (14.9%)
patients without PH and 148 (85.1%) patients with
